Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

40.39 -0.28 (-0.69%)
Streaming Delayed Price Updated: 10:40 AM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Guardant Health Named to TIME100 Most Influential Companies
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc (NASDAQ:HOOD), Moderna Inc (NASDAQ:MRNA), Palantir 
Via Benzinga
Bull Market Blastoff: 3 Stocks Targeting 56% to 91% Returns
We're heading into our third year of this raging bull market, and there doesn't appear to be any end in sight for these high-return stocks. 
Via InvestorPlace
Evaluating Guardant Health: Insights From 5 Financial Analysts
Via Benzinga
Key Takeaways From Guardant Health Analyst Ratings
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday
Via Benzinga
FDA Advisory Panel Supports Approval Of Guardant Health's Blood Test For Colorectal Cancer Screening
FDA panel recommends approval for Guardant Health's Shield blood test for colorectal cancer screening. 
Via Benzinga
Exposures Product Safety
Guardant Health Rockets After FDA Panel Recommends Approval For Blood-Based Colon Cancer Test
The companies are likely to soon battle it out in the colon cancer screening market. 
Via Investor's Business Daily
Exposures Product Safety
FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
From Guardant Health, Inc.
Via Business Wire
Analyst Expectations For Guardant Health's Future
Via Benzinga
Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
What's Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday?
FDA staff reviewers raise concerns over Guardant Health's experimental Shield blood test for colorectal cancer, citing low sensitivity in detecting certain tumor types. Shield aims to improve early CRC... 
Via Benzinga
Exposures Product Safety
Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
From Guardant Health, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
GH Stock Earnings: Guardant Health Beats EPS, Beats Revenue for Q1 2024
GH stock results show that Guardant Health beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
From Guardant Health, Inc.
Via Business Wire
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday
Via Benzinga
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
From Guardant Health, Inc.
Via Business Wire
Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales
The companies are working to detect colon cancer and precancerous markers in blood and/or stool. 
Via Investor's Business Daily
Better Than ChatGPT? New Super AI Bot Says Buy These 3 Stocks.
These stocks are solid buys according to the advanced AI model Claude 3, which has been touted as potentially superior to ChatGPT. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

"

"